We Are This Close to "Designer Babies"
By Nina Liss-Schultz,
Mother Jones
| 02. 08. 2016
[cites CGS' Marcy Darnovsky]
Untitled Document
On February 1, scientists from the United Kingdom's Francis Crick Institute got the okay to start research on human embryos using a new genome editing technology called CRISPR. Their work, which will mark only the second time CRISPR has been applied to humans, will use embryos to try to understand the very early stages of human development and pinpoint the genes causing miscarriages and fetal defects.
Not surprisingly, the Crick project has reignited a firestorm of debate over the ethics of human gene editing. "This is the first step in a well mapped-out process heading to genetically modified babies, and a future of consumer eugenics," said Dr. David King, director of Human Genetics Alert, in response to the news.
CRISPR is essentially a cellular scalpel. The small enzyme works by moving through the body's cells and cutting away at precise pieces of the genome—something that's never before been possible to do with such efficiency and ease. Since 2012, it's been used to cut out the gene mutations leading to HIV and sickle cell anemia. Last spring...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.30.2026
A research program at the National Institutes of Health released the world’s largest database of human genomes and paired them with clinical data, officials announced Tuesday, paving the way for a new era of study in personalized medicine.
The All...
By Anna Louie Sussman, The New York Times | 07.01.2026
Birthrates in much of the developed world are at record lows, but there’s one demographic group that’s exploring new frontiers of fertility: ultrawealthy men. Deploying nearly limitless resources, a small number of them are reproducing at such an extraordinary scale...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Anna Rogers, Mother Jones | 06.19.2026